1	Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR
2	assay with build-in screening functionality for DelHV69/70- and N501Y variants
3	such as B.1.1.7
4	
5	Dominik Nörz ¹ . Moritz Grunwald ¹ . Flaminia Olearo ¹ . Nicole Fischer ¹ . Martin Aepfelbacher ¹ . Susanne
6	Pfefferle ¹ und Marc Lütgehetmann ¹
7	
8	¹ University Medical Center Hamburg-Eppendorf (UKE), Institute of Medical Microbiology, Virology
9	and Hygiene, Hamburg, Germany
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	Address correspondence to:
23	Marc Lütgehetmann
25	Institute of Medical Microbiology, Virology and Hygiene
26	Martinistraße 52
27	D-20246 Hamburg
28	mluetgeh@uke.de
29	
30	
31	

32

33 1 Abstract

Background: New SARS-CoV-2 variants with increased transmissibility, like B.1.1.7 from 34 England or B1.351 from South Africa, have caused considerable concern worldwide. In order 35 to contain the spread of these lineages, it is of utmost importance to have rapid, sensitive and 36 high-throughput detection methods at hand. Methods: Analytical sensitivity was assessed for 37 38 both wild-type SARS-CoV-2 and B.1.1.7 lineage by serial dilution. A total of 141 clinical samples were subjected to the test and results compared to a commercial manual typing-PCR assay 39 and NGS. Results: The multiplex assay is highly sensitive for detection of SARS-CoV-2 RNA in 40 clinical samples, with an LoD of 25.82 cp/ml (CI: 11.61 - 57.48). LoDs are slightly higher for the 41 42 HV68/70 deletion (111.36 cp/ml; CI: 78.16 - 158.67) and the N501Y SNP (2548.04 cp/ml, CI: 1592.58 - 4076.73). A total of 141 clinical samples were tested with the assay, including 16 samples containing 43 44 SARS-CoV-2 of the B.1.1.7 lineage. Three non-B.1.1.7 samples contained a HV69/70 deletion. All were correctly identified by the multiplex assay. **Conclusion:** We describe here a highly sensitive, fully 45 automated multiplex PCR assay for the simultaneous detection of del-HV69/70 and N501Y 46 that can distinguish between lineages B.1.1.7 and B1.351. The assay allows for high-47 48 throughput screening for relevant variants in clinical samples prior to sequencing.

49

50 2 Introduction:

A number of novel SARS-CoV-2 variants that emerged in fall 2020, some of which show increased transmissibility and possible immune escape, are increasingly attracting worldwide attention (1, 2).

54 The B.1.1.7 lineage (VOC202012/01, 501Y.V1) first emerged in southern England and is notable for an unusually high number of mutations with no direct common ancestor 55 compared to previous sequences (3, 4). In particular, non-synonymous spike-gene mutations 56 such as the N501Y SNP (single nucleotide polymorphism) may lead to changes in receptor 57 binding properties (5). Another variant, B.1.351 (501Y.V2) first described in south Africa, is 58 59 characterized by the same spike mutation, along with E484K and others (6). Both have largely replaced previously circulating lineages in their respective areas of origin, indicating improved 60 61 host adaptation and immune evasion.

62

As a result of increased awareness in public health and science institutions, there has been a rapidly growing demand for whole genome sequencing worldwide in order to recognize and map the spread of these emerging variants. In this context, the speed and scalability of fully automated RT-PCR can be highly beneficial to pre-screen samples for relevant mutations.

The aim of this study was to create and validate a high-throughput first-line screening assay with the build-in ability to discriminate between relevant SARS-CoV-2 variants such as B.1.1.7 and B.1.351 on a fully automated sample-to-result PCR-platform (7). Inhouse assays have previously been used successfully for SARS-CoV-2 detection and diagnostics with this system via its open mode (Cobas Omni Utility Channel) (8).

72

73 **3 Multiplex assay setup**

The basic rationale of the multiplex assay was to combine two highly sensitive diagnostic SARS-CoV-2
PCR assays with additional assays to simultaneously detect relevant mutations. The SC2-assay by the
US CDC (N-gene, SC2-N) was modified to serve as Pan-SCoV2 target (9). A publicly available diagnostic

S-gene assay by Zhen et al. serves as second target (SC2-S) (10), while also featuring a drop-out phenomenon in the presence of a HV69/70 deletion due to probe location, which is rescued by an additional Taqman-probe (S-Del) that allows differentiation for wild-type and del-HV69/70. An additional assay was designed (using Beacon designer and PrimerQuest software) and integrated into the multiplex to detect the N501Y SNP. See *Figure 1* for a schematic overview of the PCRs and their target regions.





83



84

86 Figure 1:

a) Schematic overview of the primers and probes used in the novel multiplex assay and their target 87 regions within the SARS-CoV-2 lineages (wildtype (WT) and B.1.1.7). SARS-CoV-2 Spike SC2 PCR targets 88 the spike gene (S1) of both lineages, with probe-1 detecting the wildtype sequence and probe 2 being 89 90 specific for the HV69/70 deletion of the B.1.1.7 lineage. The SARS-CoV-2 N501YPCR targeting the 91 receptor binding domain (RBD) is specifically designed for detecting the N501Y SNP. Both lineages are 92 detected by the third PCR targeting the N-gene (N). 93 b) Exemplary amplification curves for low concentration SARS-CoV-2 wild-type and B.1.1.7 as seen in 94 the Utility Channel optimization software.

95

Primers and Probes were added to MMX-R2 to form the MMR2 mastermix and loaded into cobas omni
utility channel cassettes, according to instructions by the manufacturer. Final concentrations of
primers and probes are indicated in *table 1*. The utility channel run protocol is outlined in *table 2*.

99 The cobas 6800/8800 internal control (IC) is a spike-in (packaged) RNA target, which is 100 automatically added during extraction by the system. MMRX-R2-reagent already contains the 101 internal control assay by default; the respective sequences are not disclosed by the 102 manufacturer. The IC acts as a full process control in the same way as in commercial cobas 103 6800/8800 IVD tests manufactured by Roche.

104

105

Assay	Primer/Probe	Sequence (5' - 3')	Conc. [nM]	Inclusivity	Ref.
Pan-SARS-CoV-2 SC2-N	Fwd: Rev: Probe:	S'-CTG CAG ATT TGG ATG ATT TCT (OMe-C) C -3' S'- CCT TGT GTG GTC TGC ATG AGT T (Ome-U) A G -3' S'- Atto620- ATT GCA ACA (BMN-Q620)ATC CAT GAG CAG TGC TGA CTC -BMN- Q620 -3'	400 400 100	SARS-CoV-2 any lineage	[9]
SARS-CoV-2 Spike SC2-S	Fwd: Rev: Probe-1: Probe-2:	5'- TCA ACT CAG GAC TTG TTC T (OMe-U) A C - 3' 5'- TGG TAG GAC AGG GTT AT (Ome-C) AAA C -3' 5'- Fam- TGG TCC CAG (ZEN)AGA CAT GTA TAG CAT -Iowa Black NFQ -3' 5'- YakYellow- TGG TCC CAG A(+G)A T(+A)G C(+A)T -BHQ1	400 400 75 75	SARS-CoV-2 Probe-1: HV69/70 WT Probe-2: del-HV69/70	[10]
SARS-CoV-2 Spike N501Y	Fwd: Rev: Probe: Blocker:	5′- CCG GTA GCA CAC CTT G (OMe-U) A AT -3' 5′- AGT TGC TGG TGC ATG TA (OMe-G) AA -3′ 5′- Atto390- CC(+A) (+A)CC CAC (+T)(+T)(+A) TGG T(+G) -BHQ1 -3' 5′- CC(+A) (+A)CC CAC (+T)(+A)(+A) TGG T(+G) -C3-Spacer -3'	400 400 150 150	Spike N501Y	[This study]

Table 1: Primers and probes were custom made by Integrated DNA Technologies (Coralville, USA), Ella Biotech GmbH (Martinsried, Germany) and biomers.net GmbH (Ulm, Germany). Final concentrations of oligonucleotides indicated above refer to concentrations within the final reaction mix. OMe-X, 2'O-methyl-RNA base. BMN-Q620, proprietary dark-quencher by biomers.net can likely be replaced with e.g. BHQ2. +X, Locked nucleic acid (LNA) base.

Software settings							
Sample type	Swab (400 µL)						
Channels	1: N501Y	2: <i>SC</i> 2-S	3: S-DEL	4: <i>SC2-N</i>	5: <i>IC</i>		
RFI	1.3	1.5	1.8	1.4	1.5		
PCR cycling condit	tions						
	UNG incubation	Pre-PCR step	1 st measurement	2 nd measurement	Cooling		
No. of cycles	No. of cycles		5	45			
No. of steps		3	2	2			
Temperature	Predefined	55°C; 60°C; 65°C	95°C; 55°C	91°C; 58°C	Predefined		
Hold time		120 s; 360 s; 240 s	5 s; 30 s	5 s; 25 s			
Data acquisition		None	End of each cycle	End of each cycle			

123

Table 2: Run protocol for the SCOV2 VAR UCT assay. Configuration was done with cobas omni Utility 124

Channel software according to instructions by the manufacturer. 125

126

127

4 Evaluation of Sensitivity, Specificity and clinical 128

performance 129

130 For analytical performance evaluation, quantified SARS-COV-2 reference material (Seracare Accuplex 131 SARS-CoV-2, FluA/B and RSV Verification Panel, Milford, USA) and patient sample containing B.1.1.7 lineage (according to SARS CoV-2 whole genome sequencing) were used to prepare dilution series in 132 pooled negative patient samples. Absolute quantification of the latter was carried out using the same 133 134 assay with preexisting linearity data and the Accuplex verification panel as reference on the cobas6800 system (11). 2-fold dilution series (8 repeats per dilution step) were used to determine lower limit of 135 136 detection.

137 To evaluate clinical performance and specificity of differentiation, a set of 101 samples RT-PCR positive for SARS-CoV-2 were subjected to the SCOV2_VAR_UCT. Of these samples, 14 were predetermined as 138 139 B.1.1.7 lineage. Presence of the respective mutations was confirmed by a set of commercial assays by 140 TIB MOL (VirSNiP Spike N501Y and Del69/70, Berlin, Germany). Presence of del-HV69/70 and N501Y 141 mutations in the non-B117 set was precluded using the same commercial assays. A further 40 SARS-142 CoV-2 negative samples (by cobas SARS-CoV-2 IVD test), and a cross-reactivity panel containing various 143 respiratory pathogens (supplementary table 1) were tested with the assay to assess overall specificity. 144 145 Overall analytic LoD (95% chance of detection) was determined as 25.82 cp/ml (CI: 57.48 – 11.61) (SC2-S LoD: 73.89; CI: 151-03 – 36.16. SC2-N LoD: 11.13, CI 16.02 – 7.73), as seen in *supplementary table 2*. 146 147 There were no significant differences with B.1.1.7 lineage (Lod: 20.37, CI: 97.86 – 20.37) (S-DEL LoD: 148 111.36; CI: 158.67 – 78.16. SC2-N LoD: 20.37; CI: 97.86 – 20.37). Limit for successful detection of an

149 N501Y SNP was 2548.04 cp/ml (CI: 4076.73 – 1592.58), indicating that the N501Y SNP-assay is about

150 100-fold less sensitive than the two diagnostic-grade SARS-CoV-2 assays.

Of the 101 SARS-CoV-2 positive samples, all were correctly identified by the SCOV2_VAR_UCT. 16 B.1.1.7 lineage samples were classified as positive for N501Y and del-HV69/70. 3 of the 85 non-B.1.1.7 samples were positive for del-HV69/70, but not N501Y, which was confirmed by the TIB MOL reference assays (*table 3*). This is in line with existing data showing sporadic occurrences of del-HV69/70 mutations within the endemic SARS-CoV-2 population (approx. 6%).

- 156
- 157
- 158
- 159
- 160
- 161

	SCOV2_VAR_UCT				
	Target-1: N501Y	Target-2: SC2-S	Target-3: S-Del	Target-4: SC2-N	Total
<u>SARS-CoV-2 positive</u> Non-B.1.1.7, HV69/70 WT	0/82	82/82	0/82	82/82	82
Non-B.1.1.7, Del-HV69/70	0/3	0/3	3/3	3/3	3
B.1.1.7 lineage	16/16	0/16	16/16	16/16	16
SARS-CoV-2 negative	0/40	0/40	0/40	0/40	40
				Total Samples	141

162

163 Table 3: Clinical samples (UTM based) were predetermined positive or negative in routine diagnostics (commercial and inhouse methods) and checked for the Del-69/70 and N501Y spike-gene mutations 164 165 using commercial VirSNiP assays by TIB MOL (Berlin, Germany). B.1.1.7 lineage samples were predetermined by whole genome sequencing. All samples and mutations were correctly detected by 166 167 the SCOV2_VAR assay.

168

169

170

Discussion and Conclusion 5 171

172 Diagnostic labs in Europe are increasingly confronted with demands for rapid differentiation of SARS-173 CoV-2 isolates due to concerns about potentially higher transmissibility and immune escape with 174 recently emerged lineages such as B.1.1.7 and B1.351 (1, 6). Previous reports have demonstrated how 175 inclusivity issues of commercial assays such as the "TaqPath RT-PCR COVID-19 kit" (Thermo Fischer 176 Scientific, USA) can coincidentally be used to pre-screen for B.1.1.7 lineage variants because of a dropout phenomenon in one of the targets associated with del-HV69/70 (12). However, this method runs 177

178 the risk of misinterpreting sporadic HV69/70 deletions, of which we found three within the B.1.1.7 179 negative set. Mutations like N501Y have independently occurred multiple times in areas with high 180 incidence rates, implying advantages in an environment of high background host-immunity. Their 181 relevance may further grow in the context of ongoing vaccination campaigns. Commercial solutions 182 for SARS-CoV-2 SNP detection such as the TIB MOL VirSNiP-kits are in the process of entering the 183 diagnostics market; however, they mostly consist of manual protocols, thus limiting their suitability for large scale application. The SCOV2 VAR UCT is able to detect both the del-HV69/70 and N501Y 184 185 mutations, relevant for B.1.1.7 and B1.351 and further adaptions can be implemented to also pick up 186 new emerging SNPs if necessary. It is self-evident that such methods cannot be a replacement for 187 whole genome sequencing; they do, however, represent a valuable asset to quickly detect clusters and 188 help better direct NGS capacities.

In conclusion, the SCOV2_VAR_UCT multiplex presented in this study combines highly sensitive SARS-CoV-2 detection with relatively reliable identification of the B.1.1.7 lineage by detecting two hallmark mutations. Furthermore, other lineages featuring the N501Y SNP, but lacking the deletion, would also be recognized as abnormal for further investigation. It can thus be used either as a secondary assay for pre-screening prior to sequencing, or as a first-line diagnostic assay. Using the cobas6800/8800 automated systems, this setup can be employed for high-throughput screening for B.1.1.7 and other variants, requiring minimal hands-on time.

196

6 Author contribution

ML, SP, DN, FO, NF and MA conceptualized and supervised the study. DN and MG performed
the experiments. DN, ML, SP, NF, FO, and MA wrote and edited the manuscript. All authors
agreed to the publication of the final manuscript.

201

202 7 Competing interest

203 ML received speaker honoraria and related travel expenses from Roche Diagnostics.

204 All other authors declare no conflict of interest.

205

206 References:

2071.Kirby T. 2021. New variant of SARS-CoV-2 in UK causes surge of COVID-19. The Lancet208Respiratory Medicine 9:e20-e21.

- Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola
 JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Nair MS, Huang Y, Ho
 DD. 2021. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody
 Neutralization. bioRxiv doi:10.1101/2021.01.25.428137:2021.01.25.428137.
- Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera 213 3. 214 G, O'Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman 215 NJ, McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, 216 Sillitoe J, Kwiatkowski DP, Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, 217 Ferguson NM. 2021. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from 218 epidemiological linking and genetic data. medRxiv 219 doi:10.1101/2020.12.30.20249034:2020.12.30.20249034.
- 2204.Kemp S, Harvey W, Lytras S, Carabelli A, Robertson D, Gupta R. 2021. Recurrent emergence221and transmission of a SARS-CoV-2 Spike deletion H69/V70. bioRxiv222doi:10.1101/2020.12.14.422555:2020.12.14.422555.
- 2235.Luan B, Wang H, Huynh T. 2021. Molecular Mechanism of the N501Y Mutation for Enhanced224Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor. bioRxiv225doi:10.1101/2021.01.04.425316:2021.01.04.425316.
- 226 6. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, 227 228 Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao M, 229 Korsman S, Davies M-A, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-230 Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenço J, Alcantara LCJ, 231 Pond SLK, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. 2020. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 232 233 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 234 doi:10.1101/2020.12.21.20248640:2020.12.21.20248640.
- Poljak M, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, Avšič Županc T, Petrovec
 M. 2020. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch

All rights reserved. No reuse allowed without permission.

- during 48 hours in the midst of the COVID-19 pandemic. Journal of Clinical Microbiology
 doi:10.1128/jcm.00599-20:JCM.00599-20.
- Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. 2020. Evaluation of a quantitative RT-PCR
 assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput
 system. Eurosurveillance 25:2000152.
- 242 9. CDC. 2020. Research Use Only CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay Real-Time
 243 RT-PCR Primers and Probes. CDC Website.
- Zhen W, Berry GJ. 2020. Development of a New Multiplex Real-Time RT-PCR Assay for Severe
 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. The Journal of molecular
 diagnostics : JMD 22:1367-1372.
- 247 11. Nörz D, Frontzek A, Eigner U, Oestereich L, Fischer N, Aepfelbacher M, Pfefferle S, 248 Lütgehetmann M. 2020. Pushing beyond specifications: Evaluation of linearity and clinical performance of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in blood 249 250 and other materials outside recommendations. medRxiv 251 doi:10.1101/2020.05.28.20115469:2020.05.28.20115469.
- Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, Regue H, Semanas Q, d'Aubarede
 C, Billaud G, Laurent F, Gonzalez C, Mekki Y, Valette M, Bouscambert M, Gaudy-Graffin C, Lina
 B, Morfin F, Josset L. 2021. Two-step strategy for the identification of SARS-CoV-2 variant of
 concern 202012/01 and other variants with spike deletion H69-V70, France, August to
 December 2020. medRxiv doi:10.1101/2020.11.10.20228528:2020.11.10.20228528.